Technical Analysis for HRTX - Heron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 23.78 -3.49% -0.86
HRTX closed down 3.49 percent on Friday, March 22, 2019, on 1.34 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical HRTX trend table...

Date Alert Name Type % Chg
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.49%
Mar 21 Inside Day Range Contraction -3.49%
Mar 21 Oversold Stochastic Weakness -3.49%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.72%
Mar 20 Up 3 Days in a Row Strength -3.72%
Mar 20 Oversold Stochastic Weakness -3.72%
Mar 19 Slingshot Bearish Bearish Swing Setup -3.37%

Older signals for HRTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Medicine Health Pharmaceutical Clinical Medicine Oncology Chemotherapy Cancer Treatments Antineoplastic Drugs Drug Delivery Occupational Safety And Health Injectable Pharmaceuticals
Is HRTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 11 Heron's HTX-011 shows treatment benefit in postop pain study; shares up 1%
Mar 11 77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy
Mar 5 Report: Exploring Fundamental Drivers Behind Caesars Entertainment, Party City Holdco, Rowan Companies, TiVo, Heron Therapeutics, and Cimarex Energy — New Horizons, Emerging Trends, and Upcoming Developments
Mar 4 Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference
Feb 26 FDA OKs expanded label for Heron's Cinvanti
Feb 26 Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push
Feb 22 Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
Feb 22 Heron Therapeutics: 4Q Earnings Snapshot
Feb 22 Heron Therapeutics misses by $0.17, beats on revenue
Feb 22 Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Recent Corporate Progress
See more HRTX news...
Indicators
Indicator Value
52 Week High 42.9
52 Week Low 21.25
Average Volume 848,362
200-Day Moving Average 30.8865
50-Day Moving Average 26.4372
20-Day Moving Average 25.7735
10-Day Moving Average 24.518
Average True Range 1.021
ADX 25.25
+DI 14.1459
-DI 30.2544
Chandelier Exit (Long, 3 ATRs ) 25.637
Chandelier Exit (Short, 3 ATRs ) 26.503
Upper Bollinger Band 28.7142
Lower Bollinger Band 22.8328
Percent B (%b) 0.16
BandWidth 22.819563
MACD Line -0.749
MACD Signal Line -0.5814
MACD Histogram -0.1676
Fundamentals Value
Market Cap 1.29 Billion
Num Shares 54.1 Million
EPS -4.15
Price-to-Earnings (P/E) Ratio -5.73
Price-to-Sales 59.70
Price-to-Book 11.60
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.47
Resistance 3 (R3) 25.65 25.26 25.19
Resistance 2 (R2) 25.26 24.83 25.17 25.10
Resistance 1 (R1) 24.52 24.56 24.32 24.34 25.00
Pivot Point 24.13 24.13 24.03 24.04 24.13
Support 1 (S1) 23.39 23.70 23.20 23.22 22.56
Support 2 (S2) 23.00 23.43 22.91 22.46
Support 3 (S3) 22.26 23.00 22.37
Support 4 (S4) 22.09